• Product NameRecombinant Human Insulin-like Growth Factor-Binding Protein 4, Insect Cells Derived
• Host SpeciesInsect Cell
• Purification> 97 % by SDS-PAGE and HPLC analyses.
• Biological ActivityFully biologically active when compared to standard. The ED50 as determined by its ability to inhibit IGF-II induced proliferation of MCF-7 cells is less than 0.1 μg/ml, corresponding to a specific activity of > 1.0 x10⁴ IU/mg in the presence of 14 ng/ml of rHuIGF-II.
• EndotoxinLess than 0.1 EU/ug of rHuIGF-BP4, Insect Cell as determined by LAL method.
• Calculated MW The apparent molecular weight is about 30 kDa in SDS-PAGE under reducing conditions, containing 237 amino acids.
• Target Sequence DEAIHCPPCS EEKLARCRPP VGCEELVREP GCGCCATCAL GLGMPCGVYT PRCGSGLRCY PPRGVEKPLH TLMHGQGVCM ELAEIEAIQE SLQPSDKDEG DHPNNSFSPC SAHDRRCLQK HFAKIRDRST SGGKMKVNGA PREDARPVPQ GSCQSELHRA LERLAASQSR THEDLYIIPI PNCDRNGNFH PKQCHPALDG QRGKCWCVDR KTGVKLPGGL EPKGELDCHQ LADSFRE
• Formulation Lyophilized from a 0.2 μm filtered concentrated solution in 20mM Tris-HCl, pH 8.0, 150mM NaCl.
• Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.- 12 months from date of receipt, -20 to -70 ˚C as supplied.- 1 month, 2 to 8 ˚C under sterile conditions after reconstitution.- 3 months, -20 to -70 ˚C under sterile conditions after reconstitution.

IGFBP-4 (insulin-like growth factor binding protein 4) is member of the IGFBP family of structurally similar secreted glycoproteins that maintain IGF-I and IGF-II in the circulation and direct them to their target tissues. IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors. IGFBP-4 consistently inhibits several cancer cells in vivo and in vitro.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting